High Doses of Daunorubicin during Induction Therapy of Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Prospective Clinical Trials

The right dose of daunorubicin (DNR) for the treatment of newly diagnosed acute myeloid leukemia (AML) is uncertain. Previous trials have shown conflicting results concerning the efficacy of high or low doses of daunorubicin to induction chemotherapy for newly diagnosed AML. A systematic review and...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Qiang, Zhou, Lixin, Xu, Shuangnian, Li, Xi, Zou, Yunding, Chen, Jieping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4439155/
https://www.ncbi.nlm.nih.gov/pubmed/25993000
http://dx.doi.org/10.1371/journal.pone.0125612

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4439155/
https://www.ncbi.nlm.nih.gov/pubmed/25993000
http://dx.doi.org/10.1371/journal.pone.0125612

Ejemplares similares